Genomics and Transcriptomics Market: Global Opportunity Analysis and Industry Forecast, 2023-2030 Market

Genomics is the study of genes and their functioning. Genomics intends to understand the structure of the genome, includes gene mapping, DNA sequencing, and allows exploring the molecular mechanisms and also the interplay of environmental and genetic factors in living organisms. The Transcriptomics is said to be the study of transcriptomes, the complete set of RNA transcripts produced by the genome at any one time. It is especially focused on how transcript patterns are affected by development, disease, or environmental factors such as hormones, drugs, etc. It involves the determination of high-throughput data pertaining to the organizational structure of cell content from the tissue and also cell specimens.

COVID-19 scenario analysis:

The outbreak of the coronavirus disease has led the Pharmaceutical and Biotechnology industries to join hands with the government in order to develop vaccines for the management of the disease. Furthermore, around 115 vaccine candidates and approximately 155 molecules are proposed to be showing its effect on the disease and hence are under the R&D pipeline.  During this outbreak, the pre-existing drugs were to be used would have been a better option, as the clinical trials take longer period. Therefore, the drug such as Hydrochloroquine was observed to be experiencing higher demand in the forecast period.  Such increase in the demand for these drugs has offered huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Due to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a significant growth in the future.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

The major factors which are anticipated to affect the market include, emerging potential of spatial genomic analysis as cancer diagnostic tool, advent of fourth generation of sequencing (in situ sequencing) and the rise in need the alternatives would boost the industry in the forecast period. Furthermore, introduction of novel platforms and technologies for genomics and transcriptomics studies, has posed greater opportunities for the market to grow in the coming years. However, the higher investment may hinder the market growth.

New product advancements to flourish the market

In February 2018, Dovetail Genomics, the industry leader in the use of proximity ligation and advanced informatics for genomic solutions, announced that it is enabling new areas of human disease research with the introduction of Dovetail Hi-C and Fix-C with Selva SV Detection Software as a Service. In an industry first, the company is leveraging its proven proximity ligation technology to enable researchers to better understand human disease through the 3-D structure of the genome.

In January 2018, ReadCoor, Inc., a company reinventing genomics and pathology with its panomic spatial sequencing platform, announced a grant from the Chan Zuckerberg Initiative (CZI) and DAF, an advised fund of Silicon Valley Community Foundation, to spatially map cortical cells utilizing Fluorescent in situ Sequencing (FISSEQ) for the Human Cell Atlas.

Surge in mergers and acquisitions to boost the market

In December 2018, 10x Genomics announced the acquisition of Stockholm-based Spatial Transcriptomics, a pioneer in the emerging field of spatial genomics. The field offers invaluable insight into understanding disease by using data that was previously beyond the reach of modern methods. This opens up a field of possibilities within disease areas, such as oncology, neurology and immunology, as well as in the broader area of biology.

In March 2017, Takara Bio USA Holdings, Inc. announced that it had completed the acquisition of WaferGen Bio-systems, Inc. WaferGen became a wholly owned subsidiary of TBUSH. TBUSH is a wholly owned subsidiary of Takara Bio Inc., which is among the leading global biotechnology and life science companies headquartered in Shiga, Japan. Takara Bio USA, Inc. is a wholly owned subsidiary of TBUSH, and both TBUSA and TBUSH are part of the global Takara Bio Group.

Key benefits of the report:

• This study presents the analytical depiction of the global Genomics and Transcriptomics industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Genomics and Transcriptomics market share.
• The current market is quantitatively analyzed to highlight the global genomics and transcriptomics market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed global genomics and transcriptomics market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the genomics and transcriptomics market research report:

• Which are the leading market players active in the genomics and transcriptomics market?
• What current trends will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities in the market?
• What are the projections for the future that would help in tasking further strategic steps?

 Genomics and Transcriptomics Market: Global Opportunity Analysis and Industry Forecast, 2020–2027 Report Highlights